<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838890</url>
  </required_header>
  <id_info>
    <org_study_id>CA198-001</org_study_id>
    <nct_id>NCT00838890</nct_id>
  </id_info>
  <brief_title>A Study of BMS-863233 in Patients With Hematologic Cancer</brief_title>
  <official_title>A Phase 1/2, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-863233 in Subjects With Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      To determine safety, tolerability and maximum tolerated dose of BMS-63233/XL413 in subjects
      with Refractory Hematologic Cancer
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine maximum tolerated dose and anti-tumor activity of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer</measure>
    <time_frame>Every 21 or 28 days until maximum tolerated dose is reached</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer</measure>
    <time_frame>Every 21 or 28 days until the MTD is reached</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the pharmacokinetics of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer</measure>
    <time_frame>Every 21 or 28 days until the MTD is reached</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the anti-tumor activity of BMS-863233/XL413 when administered to subjects with refractory Hematologic Cancer</measure>
    <time_frame>Every 21 or 28 days until the MTD is reached</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Refractory Hematologic Cancer</condition>
  <arm_group>
    <arm_group_label>Cdc7-inhibitor (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cdc7-inhibitor (B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cdc7-inhibitor (BMS-863233)</intervention_name>
    <description>Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months</description>
    <arm_group_label>Cdc7-inhibitor (A)</arm_group_label>
    <other_name>BMS-863233</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cdc7-inhibitor (BMS-863233)</intervention_name>
    <description>Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months</description>
    <arm_group_label>Cdc7-inhibitor (B)</arm_group_label>
    <other_name>BMS-863233</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML by current WHO diagnostic criteria, any FAB type (except APML), Refractory ALL,
             Accelerated/blast phase CML and Refractory MDS with total IPSS score of 2 or higher

          -  ECOG performance status &lt;= 2

          -  Accessible for treatment, PK sample collection and required study follow-up

          -  Total Bilirubin ≤ 1.5 x ULN and ALT, AST ≤ 3 x ULN

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Subjects with Acute Promyelocytic leukemia disease or CNS leukemia disease)

          -  Hyperleukocytosis (defined as peripheral WBC &gt;50,000/uL)

          -  Treatment with any other investigational agent for any indication within 30 days of
             protocol enrollment

          -  Subjects a history of gastrointestinal disease

          -  Subjects less than four weeks from allogenic or autologous stem cell transplant
             infusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <disposition_first_submitted>June 21, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2015</disposition_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

